Supportive care in patients with advanced non-small-cell lung cancer

M. Di Maio, F. Perrone, C. Gallo, R. V. Iaffaioli, L. Manzione, F. V. Piantedosi, S. Cigolari, A. Illiano, S. Barbera, S. F. Robbiati, E. Piazza, G. P. Ianniello, L. Frontini, E. Veltri, F. Castiglione, F. Rosetti, E. De Maio, P. Maione, C. Gridelli

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.

Original languageEnglish
Pages (from-to)1013-1021
Number of pages9
JournalBritish Journal of Cancer
Volume89
Issue number6
DOIs
Publication statusPublished - Sep 15 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Patient Care
Antiemetics
Pharmaceutical Preparations
Drug Therapy
Adrenal Cortex Hormones
Gastrointestinal Agents
Drug-Related Side Effects and Adverse Reactions
Cisplatin
Analgesics
Therapeutics

Keywords

  • Concomitant drugs
  • Lung cancer
  • Polypharmacotherapy
  • Supportive care

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Di Maio, M., Perrone, F., Gallo, C., Iaffaioli, R. V., Manzione, L., Piantedosi, F. V., ... Gridelli, C. (2003). Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer, 89(6), 1013-1021. https://doi.org/10.1038/sj.bjc.6601236

Supportive care in patients with advanced non-small-cell lung cancer. / Di Maio, M.; Perrone, F.; Gallo, C.; Iaffaioli, R. V.; Manzione, L.; Piantedosi, F. V.; Cigolari, S.; Illiano, A.; Barbera, S.; Robbiati, S. F.; Piazza, E.; Ianniello, G. P.; Frontini, L.; Veltri, E.; Castiglione, F.; Rosetti, F.; De Maio, E.; Maione, P.; Gridelli, C.

In: British Journal of Cancer, Vol. 89, No. 6, 15.09.2003, p. 1013-1021.

Research output: Contribution to journalArticle

Di Maio, M, Perrone, F, Gallo, C, Iaffaioli, RV, Manzione, L, Piantedosi, FV, Cigolari, S, Illiano, A, Barbera, S, Robbiati, SF, Piazza, E, Ianniello, GP, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, De Maio, E, Maione, P & Gridelli, C 2003, 'Supportive care in patients with advanced non-small-cell lung cancer', British Journal of Cancer, vol. 89, no. 6, pp. 1013-1021. https://doi.org/10.1038/sj.bjc.6601236
Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV et al. Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer. 2003 Sep 15;89(6):1013-1021. https://doi.org/10.1038/sj.bjc.6601236
Di Maio, M. ; Perrone, F. ; Gallo, C. ; Iaffaioli, R. V. ; Manzione, L. ; Piantedosi, F. V. ; Cigolari, S. ; Illiano, A. ; Barbera, S. ; Robbiati, S. F. ; Piazza, E. ; Ianniello, G. P. ; Frontini, L. ; Veltri, E. ; Castiglione, F. ; Rosetti, F. ; De Maio, E. ; Maione, P. ; Gridelli, C. / Supportive care in patients with advanced non-small-cell lung cancer. In: British Journal of Cancer. 2003 ; Vol. 89, No. 6. pp. 1013-1021.
@article{1ea43422f9334b7793d5ff400f45ab54,
title = "Supportive care in patients with advanced non-small-cell lung cancer",
abstract = "The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90{\%}) enrolled patients. Gastrointestinal drugs (45.7{\%}), corticosteroids (33.4{\%}) and analgesics (23.8{\%}) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4{\%}) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27{\%}) and antianaemics (10 vs 4{\%}). Patients with worse PS are more exposed to corticosteroids (42 vs 30{\%}). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7{\%}) and are less frequently exposed to antiemetics (12 vs 27{\%}). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.",
keywords = "Concomitant drugs, Lung cancer, Polypharmacotherapy, Supportive care",
author = "{Di Maio}, M. and F. Perrone and C. Gallo and Iaffaioli, {R. V.} and L. Manzione and Piantedosi, {F. V.} and S. Cigolari and A. Illiano and S. Barbera and Robbiati, {S. F.} and E. Piazza and Ianniello, {G. P.} and L. Frontini and E. Veltri and F. Castiglione and F. Rosetti and {De Maio}, E. and P. Maione and C. Gridelli",
year = "2003",
month = "9",
day = "15",
doi = "10.1038/sj.bjc.6601236",
language = "English",
volume = "89",
pages = "1013--1021",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Supportive care in patients with advanced non-small-cell lung cancer

AU - Di Maio, M.

AU - Perrone, F.

AU - Gallo, C.

AU - Iaffaioli, R. V.

AU - Manzione, L.

AU - Piantedosi, F. V.

AU - Cigolari, S.

AU - Illiano, A.

AU - Barbera, S.

AU - Robbiati, S. F.

AU - Piazza, E.

AU - Ianniello, G. P.

AU - Frontini, L.

AU - Veltri, E.

AU - Castiglione, F.

AU - Rosetti, F.

AU - De Maio, E.

AU - Maione, P.

AU - Gridelli, C.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.

AB - The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.

KW - Concomitant drugs

KW - Lung cancer

KW - Polypharmacotherapy

KW - Supportive care

UR - http://www.scopus.com/inward/record.url?scp=0141956309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141956309&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601236

DO - 10.1038/sj.bjc.6601236

M3 - Article

VL - 89

SP - 1013

EP - 1021

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -